|
1
|
Shaw JP, Utz PJ, Durand DB, Toole JJ,
Emmel EA and Crabtree GR: Identification of a putative regulator of
early T cell activation genes. Science. 241:202–205. 1988.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Pan MG, Xiong Y and Chen F: NFAT gene
family in inflammation and cancer. Curr Mol Med. 13:543–554. 2013.
View Article : Google Scholar :
|
|
3
|
Jain J, McCaffrey PG, Valge-Archer VE and
Rao A: Nuclear factor of activated T cells contains Fos and Jun.
Nature. 356:801–804. 1992. View
Article : Google Scholar : PubMed/NCBI
|
|
4
|
Wu Y, Borde M, Heissmeyer V, Feuerer M,
Lapan AD, Stroud JC, Bates DL, Guo L, Han A, Ziegler SF, et al:
FOXP3 controls regulatory T cell function through cooperation with
NFAT. Cell. 126:375–387. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Robbs BK, Cruz AL, Werneck MB, Mognol GP
and Viola JP: Dual roles for NFAT transcription factor genes as
oncogenes and tumor suppressors. Mol Cell Biol. 28:7168–7181. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Flockhart RJ, Diffey BL, Farr PM, Lloyd J
and Reynolds NJ: NFAT regulates induction of COX-2 and apoptosis of
keratinocytes in response to ultraviolet radiation exposure. FASEB
J. 22:4218–4227. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chen L, Glover JN, Hogan PG, Rao A and
Harrison SC: Structure of the DNA-binding domains from NFAT, Fos
and Jun bound specifically to DNA. Nature. 392:42–48. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Abdoli R and Najafian N: T helper cells
fate mapping by Co-stimulatory molecules and its functions in
allograft rejection and tolerance. Int J Organ Transplant Med.
5:97–110. 2014.PubMed/NCBI
|
|
9
|
Medyouf H, Alcalde H, Berthier C,
Guillemin MC, dos Santos NR, Janin A, Decaudin D, de Thé H and
Ghysdael J: Targeting calcineurin activation as a therapeutic
strategy for T-cell acute lymphoblastic leukemia. Nat Med.
13:736–741. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Macián F, López-Rodríguez C and Rao A:
Partners in transcription : NFAT and AP-1. Oncogene. 20:2476–2489.
2001. View Article : Google Scholar
|
|
11
|
Stevenson AS, Gomez MF, Hill-Eubanks DC
and Nelson MT: NFAT4 movement in native smooth muscle. A role for
differential Ca2+ signalling. J Biol Chem.
276:15018–15024. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Flockhart RJ, Armstrong JL, Reynolds NJ
and Lovat PE: NFAT signalling is a novel target of oncogenic BRAF
in metastatic melanoma. Br J Cancer. 101:1448–1455. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tripathi P, Wang Y, Coussens M, Manda KR,
Casey AM, Lin C, Poyo E, Pfeifer JD, Basappa N, Bates CM, et al:
Activation of NFAT signaling establishes a tumorigenic
microenvironment through cell autonomous and non-cell autonomous
mechanisms. Oncogene. 33:1840–1849. 2014. View Article : Google Scholar
|
|
14
|
Baumgart S, Chen NM, Siveke JT, König A,
Zhang JS, Singh SK, Wolf E, Bartkuhn M, Esposito I, Heßmann E, et
al: Inflammation-induced NFATc1-STAT3 transcription complex
promotes pancreatic cancer initiation by KrasG12D. Cancer Discov.
4:688–701. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kawahara T, Kashiwagi E, Ide H, Li Y,
Zheng Y, Miyamoto Y, Netto GJ, Ishiguro H and Miyamoto H:
Cyclosporine A and tacrolimus inhibit bladder cancer growth through
down-regulation of NFATc1. Oncotarget. 6:1582–1593. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Pennisi A, Ling W, Li X, Khan S,
Shaughnessy JD Jr, Barlogie B and Yaccoby S: The ephrinB2/EphB4
axis is dysregulated in osteoprogenitors from myeloma patients and
its activation affects myeloma bone disease and tumor growth.
Blood. 114:1803–1812. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schabbauer G, Schweighofer B,
Mechtcheriakova D, Lucerna M, Binder BR and Hofer E: Nuclear factor
of activated T cells and early growth response-1 cooperate to
mediate tissue factor gene induction by vascular endothelial growth
factor in endothelial cells. Thromb Haemost. 97:988–997.
2007.PubMed/NCBI
|
|
18
|
Kavitha CV, Deep G, Gangar SC, Jain AK,
Agarwal C and Agarwal R: Silibinin inhibits prostate cancer cells-
and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB and
AP-1 activation in RAW264.7 cells. Mol Carcinog. 53:169–180. 2014.
View Article : Google Scholar
|
|
19
|
Murray OT, Wong CC, Vrankova K and Rigas
B: Phosphosulindac inhibits pancreatic cancer growth: NFATc1 as a
drug resistance candidate. Int J Oncol. 44:521–529. 2014.
|
|
20
|
Yang G, Rosen DG, Liu G, Yang F, Guo X,
Xiao X, Xue F, Mercado-Uribe I, Huang J, Lin SH, et al: CXCR2
promotes ovarian cancer growth through dysregulated cell cycle,
diminished apoptosis, and enhanced angiogenesis. Clin Cancer Res.
16:3875–3886. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Matsuo Y, Raimondo M, Woodward TA, Wallace
MB, Gill KR, Tong Z, Burdick MD, Yang Z, Strieter RM, Hoffman RM,
et al: CXC-chemokine/CXCR2 biological axis promotes angiogenesis in
vitro and in vivo in pancreatic cancer. Int J Cancer.
125:1027–1037. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wu B, Wang Y, Lui W, Langworthy M,
Tompkins KL, Hatzopoulos AK, Baldwin HS and Zhou B: Nfatc1
coordinates valve endocardial cell lineage development required for
heart valve formation. Circ Res. 109:183–192. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lee JH, Bhang DH, Beede A, Huang TL,
Stripp BR, Bloch KD, Wagers AJ, Tseng YH, Ryeom S and Kim CF: Lung
stem cell differentiation in mice directed by endothelial cells via
a BMP4-NFATc1-thrombospondin-1 axis. Cell. 156:440–455. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Jang GH, Park IS, Yang JH, Bischoff J and
Lee YM: Differential function of genes regulated by VEGF-NFATc1
signaling pathway in migration of pulmonary valve endothelial
cells. FEBS Lett. 584:141–146. 2010. View Article : Google Scholar :
|
|
25
|
Stankunas K, Ma GK, Kuhnert FJ, Kuo CJ and
Chang CP: VEGF signaling has distinct spatiotemporal roles during
heart valve development. Dev Biol. 347:325–336. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Pickens SR, Chamberlain ND, Volin MV,
Gonzalez M, Pope RM, Mandelin AM II, Kolls JK and Shahrara S:
Anti-CXCL5 therapy ameliorates IL-17-induced arthritis by
decreasing joint vascularization. Angiogenesis. 14:443–455. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Bachmann C, Krämer B, Brucker SY, Stäbler
A, Fend F, Wallwiener D, Grischke EM and Rothmund R: Relevance of
pelvic and para-aortic node metastases in early-stage ovarian
cancer. Anticancer Res. 34:6735–6738. 2014.PubMed/NCBI
|
|
28
|
Shin B, Yu J, Park ES, Choi S, Yu J, Hwang
JM, Yun H, Chung YH, Hong KS, Choi JS, et al: Secretion of a
truncated osteopetrosis-associated transmembrane protein 1 (OSTM1)
mutant inhibits osteoclastogenesis through down-regulation of the B
lymphocyte-induced maturation protein 1 (BLIMP1)-nuclear factor of
activated T cells c1 (NFATc1) axis. J Biol Chem. 289:35868–35881.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kawahara T, Kashiwagi E, Ide H, Li Y,
Zheng Y, Ishiguro H and Miyamoto H: The role of NFATc1 in prostate
cancer progression: Cyclosporine A and tacrolimus inhibit cell
proliferation, migration, and invasion. Prostate. 75:573–584. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Guérin F, Wagner M, Liné A, Zappa M,
Fasseu M, Paradis V, Vilgrain V, Van Beers BE, Legagneux J, Moreau
R, et al: Hepatic proliferation and angiogenesis markers are
increased after portal deprivation in rats: A study of molecular,
histological and radiological changes. PLoS One. 10:e01254932015.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Adinolfi E, Raffaghello L, Giuliani AL,
Cavazzini L, Capece M, Chiozzi P, Bianchi G, Kroemer G, Pistoia V
and Di Virgilio F: Expression of P2X7 receptor increases in vivo
tumor growth. Cancer Res. 72:2957–2969. 2012. View Article : Google Scholar : PubMed/NCBI
|
